Market Overview
The global OTC anti-infective medicine market size was valued at USD 13.38 billion in 2024. The market is projected to grow from USD 14.12 billion in 2025 to USD 17.13 billion by 2031, exhibiting a CAGR of 3.7% during the forecast period.
OTC anti-infective medicines are pharmaceutical agents available without prescription to prevent or treat infections. These include four major therapeutic classes: antibacterials (such as topical antibiotics), antivirals (like cold sore treatments), antifungals (including athlete's foot creams), and antiparasitics (such as lice treatments). Unlike prescription counterparts, these medications typically treat minor infections with established safety profiles.
17.13 billion by 2031 USD 13.38 billion in 2024
of 3.7%
Antibacterials Medicine Segment Dominates the Market Due to its Widespread Use
in Treating Common Bacterial Infections
The market is segmented based on type into:
Antibacterials Medicine
Antivirals Medicine
Antifungals Medicine
Antiparasitic Medicine
By Application
Retail Pharmacy Segment Leads Due to High Accessibility and Consumer-Driven Self-Care Trends
The market is segmented based on application into: Hospital
Portable Neuromonitoring Device Market
Retail Pharmacy
Retail pharmacy applications dominate as consumers seek immediate relief from minor ailments without medical consultation, bolstered by widespread availability and marketing efforts. Hospital settings, while crucial for severe cases, represent a smaller OTC portion, focusing on integrated care protocols. This bifurcation illustrates the market's dual role in preventive and acute management, with retail channels driving volume growth through point-of-sale education and product variety.
Our Key Players
GlaxoSmithKline
Merck
Pfizer
Novartis
Abbott
Sanofi
https://www.24lifesciences.com
